Literature DB >> 29097306

Conserved structural and functional aspects of the tripartite motif gene family point towards therapeutic applications in multiple diseases.

Liubov V Gushchina1, Thomas A Kwiatkowski1, Sayak Bhattacharya1, Noah L Weisleder2.   

Abstract

The tripartite motif (TRIM) gene family is a highly conserved group of E3 ubiquitin ligase proteins that can establish substrate specificity for the ubiquitin-proteasome complex and also have proteasome-independent functions. While several family members were studied previously, it is relatively recent that over 80 genes, based on sequence homology, were grouped to establish the TRIM gene family. Functional studies of various TRIM genes linked these proteins to modulation of inflammatory responses showing that they can contribute to a wide variety of disease states including cardiovascular, neurological and musculoskeletal diseases, as well as various forms of cancer. Given the fundamental role of the ubiquitin-proteasome complex in protein turnover and the importance of this regulation in most aspects of cellular physiology, it is not surprising that TRIM proteins display a wide spectrum of functions in a variety of cellular processes. This broad range of function and the highly conserved primary amino acid sequence of family members, particularly in the canonical TRIM E3 ubiquitin ligase domain, complicates the development of therapeutics that specifically target these proteins. A more comprehensive understanding of the structure and function of TRIM proteins will help guide therapeutic development for a number of different diseases. This review summarizes the structural organization of TRIM proteins, their domain architecture, common and unique post-translational modifications within the family, and potential binding partners and targets. Further discussion is provided on efforts to target TRIM proteins as therapeutic agents and how our increasing understanding of the nature of TRIM proteins can guide discovery of other therapeutics in the future.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer; Drugs; Inflammation; Protein therapy; Protein-protein interactions; RING domain; TRIM proteins

Mesh:

Substances:

Year:  2017        PMID: 29097306      PMCID: PMC5721676          DOI: 10.1016/j.pharmthera.2017.10.020

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  100 in total

1.  Subclassification of the RBCC/TRIM superfamily reveals a novel motif necessary for microtubule binding.

Authors:  Kieran M Short; Timothy C Cox
Journal:  J Biol Chem       Date:  2006-01-23       Impact factor: 5.157

2.  Type I interferon-dependent and -independent expression of tripartite motif proteins in immune cells.

Authors:  Ricardo Rajsbaum; Jonathan P Stoye; Anne O'Garra
Journal:  Eur J Immunol       Date:  2008-03       Impact factor: 5.532

Review 3.  The ubiquitin system.

Authors:  A Hershko; A Ciechanover
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

Review 4.  TRIM proteins in development.

Authors:  Francesca Petrera; Germana Meroni
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

Review 5.  Molecular mechanisms and treatment options for muscle wasting diseases.

Authors:  Markus A Rüegg; David J Glass
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011       Impact factor: 13.820

6.  Identification of a role for TRIM29 in the control of innate immunity in the respiratory tract.

Authors:  Junji Xing; Leiyun Weng; Bin Yuan; Zhuo Wang; Li Jia; Rui Jin; Hongbo Lu; Xian Chang Li; Yong-Jun Liu; Zhiqiang Zhang
Journal:  Nat Immunol       Date:  2016-10-03       Impact factor: 25.606

7.  Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha.

Authors:  Konstantin Khetchoumian; Marius Teletin; Johan Tisserand; Manuel Mark; Benjamin Herquel; Mihaela Ignat; Jessica Zucman-Rossi; Florence Cammas; Thierry Lerouge; Christelle Thibault; Daniel Metzger; Pierre Chambon; Régine Losson
Journal:  Nat Genet       Date:  2007-11-18       Impact factor: 38.330

8.  MG53-induced IRS-1 ubiquitination negatively regulates skeletal myogenesis and insulin signalling.

Authors:  Jae-Sung Yi; Jun Sub Park; Young-Mi Ham; Nga Nguyen; Na-Rae Lee; Jin Hong; Bong-Woo Kim; Hyun Lee; Chang-Seok Lee; Byung-Cheon Jeong; Hyun Kyu Song; Hana Cho; Yoon Ki Kim; Jae-Seon Lee; Kyong Soo Park; Haksub Shin; Inho Choi; Seung Hee Lee; Woo Jin Park; Shi-Young Park; Cheol Soo Choi; Peihui Lin; Malith Karunasiri; Tao Tan; Pu Duann; Hua Zhu; Jianjie Ma; Young-Gyu Ko
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

9.  Structural analysis of B-Box 2 from MuRF1: identification of a novel self-association pattern in a RING-like fold.

Authors:  Michael Mrosek; Sebastian Meier; Zöhre Ucurum-Fotiadis; Eleonore von Castelmur; Erik Hedbom; Ariel Lustig; Stephan Grzesiek; Dietmar Labeit; Siegfried Labeit; Olga Mayans
Journal:  Biochemistry       Date:  2008-09-17       Impact factor: 3.162

10.  Human TRIM gene expression in response to interferons.

Authors:  Laetitia Carthagena; Anna Bergamaschi; Joseph M Luna; Annie David; Pradeep D Uchil; Florence Margottin-Goguet; Walther Mothes; Uriel Hazan; Catherine Transy; Gianfranco Pancino; Sébastien Nisole
Journal:  PLoS One       Date:  2009-03-17       Impact factor: 3.240

View more
  22 in total

1.  Identification of a tripartite motif family gene signature for predicting the prognosis of patients with glioma.

Authors:  Sheng Xiao; Junhua Yu; Xuegang Yuan; Qianxue Chen
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

Review 2.  TRIMs: Generalists Regulating the NLRP3 Inflammasome Signaling Pathway.

Authors:  Nian-Hua Deng; Zhi-Xiang Zhou; Hui-Ting Liu; Zhen Tian; Ze-Fan Wu; Xi-Yan Liu; Wen-Hao Xiong; Zuo Wang; Zhi-Sheng Jiang
Journal:  DNA Cell Biol       Date:  2022-02-18       Impact factor: 3.311

3.  The B-box1 domain of PML mediates SUMO E2-E3 complex formation through an atypical interaction with UBC9.

Authors:  Thomas Bregnard; Affrin Ahmed; Irina V Semenova; Sandra K Weller; Irina Bezsonova
Journal:  Biophys Chem       Date:  2022-05-18       Impact factor: 3.628

4.  Loss of TRIM67 Attenuates the Progress of Obesity-Induced Non-Alcoholic Fatty Liver Disease.

Authors:  Chao Huang; Xiaoli Wei; Qihui Luo; Yu Xia; Ting Pan; Junbo He; Asad Jahangir; Lanlan Jia; Wentao Liu; Yuanfeng Zou; Lixia Li; Hongrui Guo; Yi Geng; Zhengli Chen
Journal:  Int J Mol Sci       Date:  2022-07-05       Impact factor: 6.208

5.  Expression and Significance of TRIM 28 in Squamous Carcinoma of Esophagus.

Authors:  Bo Liu; Xiujuan Li; Fengxi Liu; Fengyu Li; Shuxia Wei; Junchao Liu; Yang Lv
Journal:  Pathol Oncol Res       Date:  2018-11-27       Impact factor: 3.201

6.  E3 ligase TRIM15 facilitates non-small cell lung cancer progression through mediating Keap1-Nrf2 signaling pathway.

Authors:  Manman Liang; Lijing Wang; Zhengui Sun; Xingwu Chen; Hanli Wang; Lilong Qin; Wenying Zhao; Biao Geng
Journal:  Cell Commun Signal       Date:  2022-05-09       Impact factor: 7.525

Review 7.  E3 Ubiquitin Ligase TRIM Proteins, Cell Cycle and Mitosis.

Authors:  Santina Venuto; Giuseppe Merla
Journal:  Cells       Date:  2019-05-27       Impact factor: 6.600

8.  Nuclear localization signal in TRIM22 is essential for inhibition of type 2 porcine reproductive and respiratory syndrome virus replication in MARC-145 cells.

Authors:  Huiyuan Jing; Ran Tao; Nan Dong; Sufang Cao; Yanting Sun; Wenting Ke; Yang Li; Jinhe Wang; Yan Zhang; Hui Huang; Wang Dong
Journal:  Virus Genes       Date:  2019-08-02       Impact factor: 2.332

Review 9.  To Ubiquitinate or Not to Ubiquitinate: TRIM17 in Cell Life and Death.

Authors:  Meenakshi Basu-Shrivastava; Alina Kozoriz; Solange Desagher; Iréna Lassot
Journal:  Cells       Date:  2021-05-18       Impact factor: 6.600

10.  TRIM23 overexpression is a poor prognostic factor and contributes to carcinogenesis in colorectal cancer.

Authors:  Yudong Han; Ye Tan; Yuanyuan Zhao; Yongchun Zhang; Xinjia He; Li Yu; Haiping Jiang; Haijun Lu; Haiying Tian
Journal:  J Cell Mol Med       Date:  2020-03-30       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.